Dose Adjusted riTUXimab S/C, Etoposide, prednisoLONE, DOXOrubicin, cycloPHOSphamide and vinCRIStine. NCCP National SACT Regimen. HSE.
Regulatory approval published by the Health Service Executive.
Citation
Dose Adjusted riTUXimab S/C, Etoposide, prednisoLONE, DOXOrubicin, cycloPHOSphamide and vinCRIStine, 2023, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/dose-adjusted-rituximab-s-c-etoposide-prednisolone-doxorubicin-cyclophosphamide-and-vincristine-da-r-s-c-epoch-therapy.pdfRegulatory approvals
Approved indications from this document for cancer drugs containing at least one biomarker.
| Indication | Statements |
|---|---|
| Treatment of patients with CD20 positive diffuse large B-cell Non Hodgkin's lymphoma (NHL). | 2 |
Therapeutic response
Precision oncology relationships for therapeutic response derived from this document.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | CD20 + | Diffuse Large B-Cell Lymphoma | Cyclophosphamide, Doxorubicin, Etoposide, Prednisolone, Rituximab, Vincristine | |
| Sensitivity (+) | CD20 + | Non-Hodgkin Lymphoma | Cyclophosphamide, Doxorubicin, Etoposide, Prednisolone, Rituximab, Vincristine |